Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichii, Mitsuru, Mori, Katsuhito, Miyaoka, Daichi, Sonoda, Mika, Tsujimoto, Yoshihiro, Nakatani, Shinya, Shoji, Tetsuo, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981856/
https://www.ncbi.nlm.nih.gov/pubmed/33743638
http://dx.doi.org/10.1186/s12882-021-02304-2
_version_ 1783667598817230848
author Ichii, Mitsuru
Mori, Katsuhito
Miyaoka, Daichi
Sonoda, Mika
Tsujimoto, Yoshihiro
Nakatani, Shinya
Shoji, Tetsuo
Emoto, Masanori
author_facet Ichii, Mitsuru
Mori, Katsuhito
Miyaoka, Daichi
Sonoda, Mika
Tsujimoto, Yoshihiro
Nakatani, Shinya
Shoji, Tetsuo
Emoto, Masanori
author_sort Ichii, Mitsuru
collection PubMed
description BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone homeostasis. CASE PRESENTATION: We present here a patient undergoing hemodialysis with primary hypothyroidism receiving levothyroxine replacement, who showed decreased free thyroxine (FT4) and thyroid stimulating hormone (TSH) after starting roxadustat. Pituitary stimulation test revealed selective suppression of TSH secretion. Recovery of TSH and FT4 levels after stopping roxadustat suggested the suppression of TSH was reversible. CONCLUSIONS: Physicians should pay special attention to thyroid hormone abnormalities in treatment with roxadustat.
format Online
Article
Text
id pubmed-7981856
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79818562021-03-22 Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis Ichii, Mitsuru Mori, Katsuhito Miyaoka, Daichi Sonoda, Mika Tsujimoto, Yoshihiro Nakatani, Shinya Shoji, Tetsuo Emoto, Masanori BMC Nephrol Case Report BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone homeostasis. CASE PRESENTATION: We present here a patient undergoing hemodialysis with primary hypothyroidism receiving levothyroxine replacement, who showed decreased free thyroxine (FT4) and thyroid stimulating hormone (TSH) after starting roxadustat. Pituitary stimulation test revealed selective suppression of TSH secretion. Recovery of TSH and FT4 levels after stopping roxadustat suggested the suppression of TSH was reversible. CONCLUSIONS: Physicians should pay special attention to thyroid hormone abnormalities in treatment with roxadustat. BioMed Central 2021-03-20 /pmc/articles/PMC7981856/ /pubmed/33743638 http://dx.doi.org/10.1186/s12882-021-02304-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Ichii, Mitsuru
Mori, Katsuhito
Miyaoka, Daichi
Sonoda, Mika
Tsujimoto, Yoshihiro
Nakatani, Shinya
Shoji, Tetsuo
Emoto, Masanori
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title_full Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title_fullStr Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title_full_unstemmed Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title_short Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
title_sort suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981856/
https://www.ncbi.nlm.nih.gov/pubmed/33743638
http://dx.doi.org/10.1186/s12882-021-02304-2
work_keys_str_mv AT ichiimitsuru suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT morikatsuhito suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT miyaokadaichi suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT sonodamika suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT tsujimotoyoshihiro suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT nakatanishinya suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT shojitetsuo suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis
AT emotomasanori suppressionofthyrotropinsecretionduringroxadustattreatmentforrenalanemiainapatientundergoinghemodialysis

Ejemplares similares